Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Tanner

Showing results (811-820 of 855) with videos related to

Pageof 86
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|February 20, 2020
Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional StudyTanya Simuni, Michael C Brumm, Liz Uribe, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 22, 1998
Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinomaC Collins, J M Rommens, D Kowbel, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 17, 2020
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease ProgressionBrit Mollenhauer, Mohammed Dakna, Niels Kruse, et al.
Environmental Health Perspectives|August 13, 2013
Research on the premotor symptoms of Parkinson's disease: clinical and etiological implicationsHonglei Chen, Edward A Burton, G Webster Ross, et al.
Neurology|February 2, 2024
Evaluation of ATN<sub>PD</sub> Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson DiseaseKatheryn A Q Cousins, David J Irwin, Thomas F Tropea, et al.
Annals of Neurology|May 11, 2026
Recruitment Strategies across the Spectrum of Neuronal Synuclein DiseaseAndrew Siderowf, Laura E A Heathers, Kimberly Fabrizio, et al.
Environmental Health Perspectives|January 24, 2009
Meeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007Jeff Bronstein, Paul Carvey, Honglei Chen, et al.
Cell|June 2, 2007
Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemiaAparna Raval, Stephan M Tanner, John C Byrd, et al.
The Lancet. Neurology|June 21, 2017
Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohortsGanqiang Liu, Joseph J Locascio, Jean-Christophe Corvol, et al.
Frontiers in Aging Neuroscience|November 2, 2020
Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP)Andrea Sturchio, Luca Marsili, Joaquin A Vizcarra, et al.
Pageof 86

Showing results (811-820 of 855) with videos related to

Sort By:
Pageof 86
Movement Disorders : Official Journal of the Movement Disorder Society|February 20, 2020
Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional StudyTanya Simuni, Michael C Brumm, Liz Uribe, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 22, 1998
Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinomaC Collins, J M Rommens, D Kowbel, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 17, 2020
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease ProgressionBrit Mollenhauer, Mohammed Dakna, Niels Kruse, et al.
Environmental Health Perspectives|August 13, 2013
Research on the premotor symptoms of Parkinson's disease: clinical and etiological implicationsHonglei Chen, Edward A Burton, G Webster Ross, et al.
Neurology|February 2, 2024
Evaluation of ATN<sub>PD</sub> Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson DiseaseKatheryn A Q Cousins, David J Irwin, Thomas F Tropea, et al.
Annals of Neurology|May 11, 2026
Recruitment Strategies across the Spectrum of Neuronal Synuclein DiseaseAndrew Siderowf, Laura E A Heathers, Kimberly Fabrizio, et al.
Environmental Health Perspectives|January 24, 2009
Meeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007Jeff Bronstein, Paul Carvey, Honglei Chen, et al.
Cell|June 2, 2007
Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemiaAparna Raval, Stephan M Tanner, John C Byrd, et al.
The Lancet. Neurology|June 21, 2017
Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohortsGanqiang Liu, Joseph J Locascio, Jean-Christophe Corvol, et al.
Frontiers in Aging Neuroscience|November 2, 2020
Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP)Andrea Sturchio, Luca Marsili, Joaquin A Vizcarra, et al.
Pageof 86